Company: PBH
Filing Date: 2025-05-09
Form Type: 10-K
Source: 0001295947-25-000017
Chunk: 75

Company: Prestige Consumer Healthcare Inc.
Filing Date: 2025-05-09
Form: 10-K
Item: Item 7
Chunk 75
---
5 versus 2024.  The $10.7 million increase was mainly attributable to an increase in sales in the Gastrointestinal and Dermatologicals categories, partly offset by a decrease in sales in the Women's Health and Cough & Cold categories.  

37

Gross Profit

The following table represents our gross profit and gross profit as a percentage of total segment revenues, by segment for each of the fiscal years ended March 31, 2025 and 2024.

(In thousands)Increase (Decrease)Gross Profit 2025%2024%Amount%North American OTC Healthcare $531,139 55.3 $528,899 55.2 $2,240 0.4 International OTC Healthcare 103,324 58.1 95,549 57.2 7,775 8.1  $634,463 55.8 $624,448 55.5 $10,015 1.6 

Gross profit for 2025 increased $10.0 million, or 1.6%, versus 2024.  As a percentage of total revenues, gross profit increased to 55.8% in 2025 from 55.5% in 2024, primarily due to an increase in revenue and a decrease in freight costs in our North American OTC Healthcare segment.

North American OTC Healthcare Segment

Gross profit for the North American OTC Healthcare segment increased $2.2 million, or 0.4%, during 2025 versus 2024.  As a percentage of North American OTC Healthcare revenues, gross profit increased to 55.3% during 2025 from 55.2% during 2024. 

International OTC Healthcare Segment

Gross profit for the International OTC Healthcare segment increased $7.8 million, or 8.1%, during 2025 versus 2024.  As a percentage of International OTC Healthcare revenues, gross profit increased to 58.1% during 2025 from 57.2% during 2024, primarily due to an increase in revenue and product mix.

Contribution Margin

Contribution margin is our segment measure of profitability.  It is defined as gross profit less advertising and marketing expenses.  

The following table represents our contribution margin and contribution margin as a percentage of total segment revenues, by segment for each of the fiscal years ended March 31, 2025 and